After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...